News | February 25, 2022
Risk appetite key to innovation in pharma and biopharma
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
Clears major obesity endpoints at 80 weeks
New regulation mandates stricter prescription monitoring, sales record maintenance, and enhanced compliance across the pharmaceutical supply chain
Organizations that embrace it thoughtfully today will help shape a healthier tomorrow, for India and beyond
The event is expected to attract more than 100 senior professionals from pharmaceutical companies, CROs, regulatory agencies, and technology organisations
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
The therapy is suited for patients with severe valve leakage who face elevated surgical risk due to advanced age, frailty, or multiple medical complications
Subscribe To Our Newsletter & Stay Updated
